Immix Biopharma, Inc. Common Stock IMMX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T01:25:23.338Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:26:10.839203363Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T01:25:22.764307+00:00
Immix Biopharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 23.97 | 519.6% | 183.5% | |||
| 25Δ | ||||||
| 30Δ | 7.83 | 175.9% | 16.5% | |||
| 35Δ | 8.17 | 179.0% | 15.0% | |||
| 40Δ | 9.03 | 202.7% | 16.3% | 8.51 | 182.1% | 13.5% |
| 45Δ | 8.78 | 228.9% | 16.1% | 8.84 | 185.2% | 12.0% |
| 50Δ | 8.53 | 255.1% | 15.8% | 9.18 | 188.3% | 10.4% |
| 55Δ | 8.28 | 281.3% | 15.6% | 9.52 | 191.5% | 8.9% |
| 60Δ | 8.03 | 307.5% | 15.4% | 9.85 | 194.6% | 7.4% |
| 65Δ | 7.78 | 333.7% | 15.2% | 10.25 | 193.1% | 6.2% |
| 70Δ | 7.53 | 359.9% | 14.9% | 10.71 | 188.0% | 5.1% |
| 75Δ | 11.16 | 183.0% | 4.1% | |||
| 80Δ | 11.61 | 177.9% | 3.0% | |||
20Δ
- Pseudo strike
- 23.97
- IV
- 519.6%
- B/E move
- 183.5%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.83
- IV
- 175.9%
- B/E move
- 16.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.17
- IV
- 179.0%
- B/E move
- 15.0%
40Δ
- Pseudo strike
- 9.03
- IV
- 202.7%
- B/E move
- 16.3%
- Pseudo strike
- 8.51
- IV
- 182.1%
- B/E move
- 13.5%
45Δ
- Pseudo strike
- 8.78
- IV
- 228.9%
- B/E move
- 16.1%
- Pseudo strike
- 8.84
- IV
- 185.2%
- B/E move
- 12.0%
50Δ
- Pseudo strike
- 8.53
- IV
- 255.1%
- B/E move
- 15.8%
- Pseudo strike
- 9.18
- IV
- 188.3%
- B/E move
- 10.4%
55Δ
- Pseudo strike
- 8.28
- IV
- 281.3%
- B/E move
- 15.6%
- Pseudo strike
- 9.52
- IV
- 191.5%
- B/E move
- 8.9%
60Δ
- Pseudo strike
- 8.03
- IV
- 307.5%
- B/E move
- 15.4%
- Pseudo strike
- 9.85
- IV
- 194.6%
- B/E move
- 7.4%
65Δ
- Pseudo strike
- 7.78
- IV
- 333.7%
- B/E move
- 15.2%
- Pseudo strike
- 10.25
- IV
- 193.1%
- B/E move
- 6.2%
70Δ
- Pseudo strike
- 7.53
- IV
- 359.9%
- B/E move
- 14.9%
- Pseudo strike
- 10.71
- IV
- 188.0%
- B/E move
- 5.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.16
- IV
- 183.0%
- B/E move
- 4.1%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.61
- IV
- 177.9%
- B/E move
- 3.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 194.25% | |
| 214.63% | |
| 113.46% | |
| 123.06% | |
| 106.00% | |
| 95.32% | |
| 103.74% | |
| 103.88% | |
| 123.05% | |
| 107.82% | |
| 133.05% | |
| 109.62% | |
| 141.23% | |
| 131.13% | |
| 157.99% | |
| 132.26% | |
| 251.23% | |
| 169.10% | |
| 129.37% | |
| 123.66% | |
| 144.78% | |
| 125.03% | |
| 132.21% | |
| 124.30% | |
| 140.45% | |
| 135.70% | |
| 141.26% | |
| 116.74% | |
| 118.20% | |
| 128.67% | |
| 132.79% | |
| 126.36% | |
| 184.64% | |
| 173.27% | |
| 148.96% | |
| 147.55% | |
| 162.14% |
Biotechnology
IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.
More →IMRX
Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its proprietary drug…
More →IMTX
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in…
More →IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory…
More →IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York,…
More →INBX
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla,…
More →